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Quality of life and longevity have increased in low- and middle-income countries (LMICs) but little 
is known about how increased aging may impact neurological health (1). In their recent Lancet 
Neurology paper, Feigin and colleagues (2) shed more light on this. By reanalyzing data from the 2015 
Global Burden of Disease, the authors provided updated neurological disorder burden estimates. 
They found that Alzheimer’s disease (AD) and other dementias were the fourth-leading cause of 
deaths and disability globally, and consistently among the top three causes of disability in most 
countries (2).
Notably, the authors used proxy data from high-income countries to estimate dementia preva-
lence and mortality in LMICs due to data scarcity. This absence of epidemiological neurology data is 
partly due to a lack of screening tests and biomarker analysis adapted to local and social contexts for 
clinical decision making. In some settings, cognitive impairment assessment is the sole diagnostic 
criteria, and even this is not performed in many places (3). We believe that routine biomarker testing 
for patients with sufficient risk factors and screened for cognitive impairment would enhance clinical 
diagnosis and enrich epidemiological studies. For example, blood and cerebrospinal fluid (CSF) 
concentrations of amyloid-β, total tau, and phosphorylated tau robustly predict neurodegeneration 
progression (4). The cost-effectiveness of biomarker analyses favors their use in LMICs and may be 
particularly important in differentiating AD-like cognitive impairment from that of other causes 
(e.g., HIV), given their distinct CSF biomarker patterns (5).
Since cognitive assessment tools cannot efficiently distinguish between risk factors for AD 
(pathology), age-related dementia, and concomitant cerebrovascular disease (or other pathologies), 
biomarkers would be important in epidemiological studies aimed at revealing the true risk factors 
2Karikari et al. Neurodegeneration Biomarker Analysis in LMICs
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 201
for these diseases. In addition to tau and amyloid-β, the emerging 
biomarkers neurofilament light chain, neurogranin, and YKL-
40 sensitively predict early neurodegeneration, and age-related 
cognitive decline with or without neurodegeneration (6, 7). These 
biomarkers have great potential for identifying disease- and 
condition-specific risk factors in different environments.
A predictable challenge to the recommended approach is the 
lack of dedicated neurology diagnosis facilities. However, most 
LMICs have well-resourced public health laboratories that could 
be expanded to offer centralized biomarker testing services, 
with training and support from expert clinical biochemists 
and neurologists. These public health laboratories are equipped 
with molecular testing facilities and have been instrumental 
in managing emergencies such as the recent Zika and Ebola 
outbreaks. Governments should therefore prioritize biomarker-
supported dementia diagnosis to enhance patient care, public 
health planning, and epidemiological studies, toward achieving 
the Sustainable Development Goals and related targets to defeat 
dementia.
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